Cargando…
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor prognosis and rising incidence. Late detection and a particularly aggressive biology are the major challenges which determine therapeutic failure. In this review, we present the current status and the recent advances i...
Autores principales: | Orth, Michael, Metzger, Philipp, Gerum, Sabine, Mayerle, Julia, Schneider, Günter, Belka, Claus, Schnurr, Maximilian, Lauber, Kirsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688256/ https://www.ncbi.nlm.nih.gov/pubmed/31395068 http://dx.doi.org/10.1186/s13014-019-1345-6 |
Ejemplares similares
-
Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma
por: Li, Q., et al.
Publicado: (2020) -
Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008) -
Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018) -
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021) -
Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)